ONC201(多达维普隆)每周连续两天给药在儿童H3 K27M突变型胶质瘤患者中的安全性与药代动力学
这项1期剂量递增与扩展研究评估了口服ONC201在儿童新诊断DIPG和/或复发/难治性H3 K27M突变型胶质瘤中每周连续两天(D1D2)给药的安全性与药代动力学(PK)。12例患者接受D1D2给药,未发生剂量限制性毒性或≥3级治疗相关不良事件;DL2的PK分析显示Cmax、AUC0-24和AUC0-48存在变异性,各体重组暴露量相当。D1D2给药无蓄积,多数ONC201在第二次给药前已清除;D1D2的AUC0-48高于每周一次给药。
要点
- 12例儿童H3 K27M突变型胶质瘤患者接受D1D2 ONC201,未发生剂量限制性毒性或≥3级治疗相关不良事件。
- DL2的PK分析显示Cmax、AUC0-24和AUC0-48存在变异性,各体重组暴露量相当。
- D1D2给药无蓄积,多数ONC201在第二次给药前已清除;D1D2的AUC0-48大于每周一次给药。
核心结论
- ONC201以D1D2方案在所有剂量水平均耐受良好,并与更大的AUC0-48相关。
研究设计与样本
- 这项1期剂量递增和扩展研究纳入儿童H3 K27M突变型胶质瘤和/或DIPG患者,要求既往接受≥1线治疗(NCT03416530)。
- ONC201以D1D2方案给药,设3个剂量水平(DL;-1、1和2),DL内的实际给药剂量取决于体重。
- 安全性在所有DL中评估;PK分析在DL2中进行;接受每周一次ONC201(D1)的患者作为PK对照。
- 12例患者接受D1D2 ONC201(DL1,n=3;DL1,n=3;DL2,n=6)。
主要发现
- 12例接受D1D2 ONC201的患者中未发生剂量限制性毒性或≥3级治疗相关不良事件。
- DL2的PK分析(D1-250 mg,n=3;D1-625 mg,n=3;D1D2-250 mg,n=2;D1D2-625 mg,n=2)显示Cmax、AUC0-24和AUC0-48存在变异性,各体重组暴露量相当。
- D1D2给药无蓄积,多数ONC201在第二次给药前已清除。
- Cmax在各组间存在变异性,但似乎未随D1D2给药而增加;D1D2的AUC0-48大于每周一次给药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the safety and pharmacokinetics (PK) of oral ONC201 administered twice-weekly on consecutive days (D1D2) in pediatric patients with newly diagnosed DIPG and/or recurrent/refractory H3 K27M glioma. METHODS: This phase 1 dose-escalation and expansion study included pediatric patients with H3 K27M-mutant glioma and/or DIPG following ≥1 line of therapy (NCT03416530). ONC201 was administered D1D2 at 3 dose levels (DLs; -1, 1, and 2). The actual administered dose within DLs was dependent on weight. Safety was assessed in all DLs; PK analysis was conducted in DL2. Patients receiving once-weekly ONC201 (D1) served as a PK comparator. RESULTS: Twelve patients received D1D2 ONC201 (DL1, n = 3; DL1, n = 3; DL2, n = 6); no dose-limiting toxicities or grade ≥3 treatment-related adverse events occurred. PK analyses at DL2 (D1-250 mg, n = 3; D1-625 mg, n = 3; D1D2-250 mg, n = 2; D1D2-625 mg, n = 2) demonstrated variability in Cmax, AUC0-24, and AUC0-48, with comparable exposures across weight groups. No accumulation occurred with D1D2 dosing; the majority of ONC201 cleared before administration of the second dose. Cmax was variable between groups but did not appear to increase with D1D2 dosing. AUC0-48 was greater with D1D2 than once-weekly. CONCLUSIONS: ONC201 given D1D2 was well tolerated at all DLs and associated with greater AUC0-48.
引用
- Odia Y, Koschmann C, Vitanza NA, et al. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma. Neuro Oncol. 2024. PMID: 38400780. doi:10.1093/neuonc/noae001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。